These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 29309301)

  • 1. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
    Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
    Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
    Sasaki M; Sato Y; Nakanuma Y
    Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers.
    Liao H; Chen X; Wang H; Lin Y; Chen L; Yuan K; Liao M; Jiang H; Peng J; Wu Z; Huang J; Li J; Zeng Y
    Cancer Res; 2024 Jun; 84(11):1747-1763. PubMed ID: 38471085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational spectrum and precision oncology for biliary tract carcinoma.
    Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
    Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
    [No Abstract]   [Full Text] [Related]  

  • 5. PTEN loss and KRAS activation cooperate in murine biliary tract malignancies.
    Marsh V; Davies EJ; Williams GT; Clarke AR
    J Pathol; 2013 Jun; 230(2):165-73. PubMed ID: 23483557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.
    Plum PS; Hess T; Bertrand D; Morgenstern I; Velazquez Camacho O; Jonas C; Alidousty C; Wagner B; Roessler S; Albrecht T; Becker J; Richartz V; Holz B; Hoppe S; Poh HM; Chia BKH; Chan CX; Pathiraja T; Teo AS; Marquardt JU; Khng A; Heise M; Fei Y; Thieme R; Klein S; Hong JH; Dima SO; Popescu I; Hoppe-Lotichius M; Buettner R; Lautem A; Otto G; Quaas A; Nagarajan N; Rozen S; Teh BT; Goeppert B; Drebber U; Lang H; Tan P; Gockel I; Schumacher J; Hillmer AM
    Clin Transl Med; 2024 Jun; 14(6):e1723. PubMed ID: 38877653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel NIPBL-NACC1 Gene Fusion Is Characteristic of the Cholangioblastic Variant of Intrahepatic Cholangiocarcinoma.
    Argani P; Palsgrove DN; Anders RA; Smith SC; Saoud C; Kwon R; Voltaggio L; Assarzadegan N; Oshima K; Rooper L; Matoso A; Zhang L; Cantarel BL; Gagan J; Antonescu CR
    Am J Surg Pathol; 2021 Nov; 45(11):1550-1560. PubMed ID: 33999553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of MDM2 and TP53 genes in canine liposarcoma.
    Muscatello LV; de Biase D; Maloberti T; di Oto E; Tallini G; Pellegrino V; Bacci B; Roccabianca P; Lepri E; Crippa L; Avallone G
    Sci Rep; 2024 Jun; 14(1):14087. PubMed ID: 38890407
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Hill MA; Alexander WB; Guo B; Kato Y; Patra K; O'Dell MR; McCall MN; Whitney-Miller CL; Bardeesy N; Hezel AF
    Cancer Res; 2018 Aug; 78(16):4445-4451. PubMed ID: 29871934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
    Tang TY; Nichetti F; Kaplan B; Lonardi S; Pietrantonio F; Salvatore L; Vivaldi C; Rimassa L; de Braud F; Rizzato MD; Pavlick D; Chu R; Danner De Armas A; Sharaf R; Sokol E; Rodon Ahnert J; Ross JS; Javle M; Niger M
    Clin Cancer Res; 2023 Dec; 29(23):4853-4862. PubMed ID: 37773629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
    J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 amplification is rare in gastric cancer.
    Abdullazade S; Behrens HM; Krüger S; Haag J; Röcken C
    Virchows Arch; 2023 Dec; 483(6):795-807. PubMed ID: 37821635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma.
    Zhang M; Huang Y; Pan J; Sang C; Lin Y; Dong L; Shen X; Wu Y; Song G; Ji S; Liu F; Wang M; Zheng Y; Zhang S; Wang Z; Ren J; Gao D; Zhou J; Fan J; Wei W; Lin J; Gao Q
    Cancer Discov; 2023 Oct; 13(10):2248-2269. PubMed ID: 37486241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Immunohistochemical Analysis of Osteopontin and S100 Calcium-binding Protein P is Useful for Subclassifying Large- and Small-duct Type Intrahepatic Cholangiocarcinomas.
    Yoshizawa T; Uehara T; Iwaya M; Nakajima T; Shimizu A; Kubota K; Notake T; Kitagawa N; Masuo H; Sakai H; Hayashi H; Tomida H; Yamazaki S; Hirano S; Ota H; Soejima Y
    Am J Surg Pathol; 2024 Jun; 48(6):751-760. PubMed ID: 38584480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
    Martin-Serrano MA; Kepecs B; Torres-Martin M; Bramel ER; Haber PK; Merritt E; Rialdi A; Param NJ; Maeda M; Lindblad KE; Carter JK; Barcena-Varela M; Mazzaferro V; Schwartz M; Affo S; Schwabe RF; Villanueva A; Guccione E; Friedman SL; Lujambio A; Tocheva A; Llovet JM; Thung SN; Tsankov AM; Sia D
    Gut; 2023 Apr; 72(4):736-748. PubMed ID: 35584893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of p53 and Its Target Gene Expression as Potential Biomarkers of Cholangiocarcinoma in Thai Patients.
    Puetkasichonpasutha J; Namwat N; Sa-Ngiamwibool P; Titapun A; Suthiphongchai T
    Asian Pac J Cancer Prev; 2020 Mar; 21(3):791-798. PubMed ID: 32212809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors.
    Yoo C; Lamarca A; Choi HJ; Vogel A; Pishvaian MJ; Goyal L; Ueno M; Märten A; Teufel M; Geng L; Morizane C
    Future Oncol; 2024; 20(16):1069-1077. PubMed ID: 38214149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral heterogeneity of intrahepatic cholangiocarcinoma.
    Walter D; Döring C; Feldhahn M; Battke F; Hartmann S; Winkelmann R; Schneider M; Bankov K; Schnitzbauer A; Zeuzem S; Hansmann ML; Peveling-Oberhag J
    Oncotarget; 2017 Feb; 8(9):14957-14968. PubMed ID: 28146430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma.
    Xu S; Guo Y; Zeng Y; Song Z; Zhu X; Fan N; Zhang Z; Ren G; Zang Y; Rao W
    BMC Cancer; 2021 Feb; 21(1):152. PubMed ID: 33579226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas.
    Rehkaemper J; Korenkov M; Quaas A; Rueschoff J; Pamuk A; Zander T; Hillmer AM; Buettner R; Hoelscher AH; Bruns CJ; Loeser H; Alakus H; Schoemig-Markiefka B
    BMC Cancer; 2020 Jun; 20(1):587. PubMed ID: 32571252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.